Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors

Michio Sakai(Yao Tokushukai General Hospital), Akira Shirahata(Kitakyushu City Hospital Organization), Motoaki Chin(Nihon University), Masataka Ishimura(Kyushu University Hospital), Sho Harano(KM Biologics (Japan)), Kagehiro Amano(Tokyo Medical University Hospital), Hideyuki Takedani(University of Tokyo Hospital), Hiroyuki Ishida(Kyoto City Hospital), Hiroyoshi Watanabe(Tokushima University), Masashi Taki(St. Marianna University School of Medicine), Keiji Nogami(Nara Medical University), Masahiro Migita(Japanese Red Cross Kumamoto Hospital), Kazuo Sakashita(Nagano Children's Hospital)
Haemophilia
December 14, 2022
Cited by 5


Related Papers